Literature DB >> 12161540

Loss of heterozygosity in parathyroid glands of familial hypercalcemia with hypercalciuria and point mutation in calcium receptor.

Eva Szabo1, Tobias Carling, Ola Hessman, Jonas Rastad.   

Abstract

Development of sporadic parathyroid tumors is accompanied by loss of heterozygosity (LOH) on several chromosomes like 1p, 1q, 6q, 11q, and 15q. Here, we investigate a unique variant of familial hypercalcemia, unrelated to multiple endocrine neoplasia and hyperparathyroidism-jaw tumor syndromes, with hypercalcemia due to a point mutation in the intracellular part of the calcium receptor (CaR) gene. The hypercalcemia and hypercalciuria of the family is accompanied by age-related growth of the parathyroid glands and transition from diffuse to nodular parathyroid hyperplasia. Genome-wide screening for allelic loss was performed on nine enlarged parathyroid glands (weighing 40-680 mg) from eight parathyroidectomized members of the family (aged 22-66 yr). Using 139 fluorescent- or (32)P-labeled microsatellite markers, informative results were obtained on all examined chromosome arms and 1p, 1q, 6q, 11q, and 15q were investigated more closely. All parathyroid glands displayed allelic loss on at least one chromosomal arm (range 1-7). Most of the common loci for allelic loss corresponded to findings in sporadic parathyroid tumors, but the unique variant of familial hypercalcemia also exhibited frequent LOH on 12q (67%) and 7q (44%). LOH could not be detected at 3q, where the CaR gene is located, and additional somatic mutations in exons 2-7 of the CaR gene was not found by sequencing. The point mutation resulting in alteration of the intracellular portion of CaR seems to cause sensitivity to secondary genetic hits, with increased frequency of allelic loss (P < 0.01, r(2) = 0.66) and weight of parathyroid tumors with age in this family.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12161540     DOI: 10.1210/jcem.87.8.8759

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Neonatal Severe Hyperparathyroidism: Novel Insights From Calcium, PTH, and the CASR Gene.

Authors:  Stephen J Marx; Ninet Sinaii
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

2.  Frequent germ-line mutations of the MEN1, CASR, and HRPT2/CDC73 genes in young patients with clinically non-familial primary hyperparathyroidism.

Authors:  Lee F Starker; Tobias Akerström; William D Long; Alberto Delgado-Verdugo; Patricia Donovan; Robert Udelsman; Richard P Lifton; Tobias Carling
Journal:  Horm Cancer       Date:  2012-04       Impact factor: 3.869

3.  Novel mutations of the calcium-sensing receptor impede differential diagnosis of primary hyperparathyroidism and familial hypocalciuric hypercalcemia.

Authors:  Jagdeep Singh Bhangu; Sabina Baumgartner-Parzer; Lindsay Hargitai; Peter Mazal; Christian Scheuba; Philipp Riss
Journal:  Gland Surg       Date:  2022-01

Review 4.  Familial parathyroid tumors: diagnosis and management.

Authors:  Peter Stålberg; Tobias Carling
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

Review 5.  Molecular genetics of parathyroid disease.

Authors:  Gunnar Westin; Peyman Björklund; Göran Akerström
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

Review 6.  Uncoupling of secretion from growth in some hormone secretory tissues.

Authors:  Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2014-07-08       Impact factor: 5.958

7.  Case Report: Unusual Presentations of Loss-of-Function Mutations of the Calcium-Sensing Receptor.

Authors:  Serena Palmieri; Giorgia Grassi; Vito Guarnieri; Iacopo Chiodini; Maura Arosio; Cristina Eller-Vainicher
Journal:  Front Med (Lausanne)       Date:  2022-01-24

8.  Double jeopardy: a patient's tale of two concurrent hypercalcaemic syndromes.

Authors:  Aditi Sharma; Fatima Bahowairath; Chukwuma Uduku; Julia E Ostberg
Journal:  BMJ Case Rep       Date:  2020-08-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.